Bide Pharmatech (SH:688073) Xin Lang Cai Jing·2025-10-27 05:41Core Viewpoint - Bid Pharma's stock increased by 5.03% to 80.86 CNY per share, with a total market capitalization of 7.349 billion CNY as of October 27 [1] Company Overview - Shanghai Bid Pharma Technology Co., Ltd. was established on April 27, 2007, and went public on October 11, 2022 [1] - The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - Main business revenue composition includes: - 43.26% from molecular building block heterocyclic compounds - 23.32% from molecular building block aromatic compounds - 16.36% from molecular building block aliphatic compounds - 10.57% from catalysts and ligands - 6.49% from life science reagents [1] Fund Holdings - Huashang Fund has a significant holding in Bid Pharma, with the Huashang Health Life Mixed Fund (001106) holding 62,400 shares, representing 2.22% of the fund's net value [2] - The fund has achieved a year-to-date return of 38.95%, ranking 1935 out of 8226 in its category [2] Fund Manager Information - The fund manager of Huashang Health Life Mixed Fund is Sun Wei, who has been in the position for 2 years and 298 days [3] - The total asset size of the fund is 7.139 billion CNY, with the best return during Sun Wei's tenure being 65.96% and the worst being -11.43% [3]